John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
REDWOOD CITY, Calif., Feb. 04, 2016 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will provide a corporate update at two upcoming investor conferences.
- BIO CEO and Investor Conference – New York
OncoMed’s corporate presentation is scheduled to take place at 10:30 a.m. ET on February 8, 2016.
- Leerink Partners 5th Annual Global Healthcare Conference - New York
Paul Hastings will provide a fireside chat on Thursday, February 11 at 8:30 a.m. ET.
A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcasts will also be archived and available for replay for up to 45 days.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin-LGR. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate that is part of OncoMed’s collaboration with Celgene (IO#2) toward clinical trials in the 2016-2017 timeframe.
Please see the company's website at www.oncomed.com for additional information.
Contact:
Media & Investors
OncoMed Pharmaceuticals
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
[email protected]
(650) 995-8373
